Drug Profile

RTN 001

Alternative Names: KD-027; RTN-001; SLX 2101; SLx-2101

Latest Information Update: 01 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Surface Logix
Developer Kadmon Pharmaceuticals; Retension Pharmaceuticals; Surface Logix
Class Antihypertensives; Cardiovascular therapies; Erectile dysfunction therapies; Small molecules
Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Hypertension
Discontinued Erectile dysfunction; Raynaud's disease

Most Recent Events

31 Oct 2025 Phase-II clinical trials in Hypertension in USA (PO) (NCT07142356)
06 Aug 2025 Retension Pharmaceuticals has patent protection for RTN 001 in USA
14 Apr 2014 KD 027 is still in phase II trials for Hypertension

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com